EVAX stock news · Evaxion A/S
Get alerts for EVAX
Follow Evaxion A/S (EVAX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EVAXEvaxion won the 2026 International Prix Galien Award for its AI-Immunology™ platform.
Good for EVAXEvaxion won an international award for its AI-Immunology platform, giving the technology outside recognition. This modestly supports the company, but does not show that it has produced successful medicines or sales.
Evaxion Reports Phase II Results for EVX-01 in Advanced Melanoma
Good for EVAXEvaxion's EVX-01 showed a 75% response rate with pembrolizumab in advanced melanoma. Lasting responses favor its outlook, though few patients were studied.
12 health care companies are changing a lot in Friday's early trading.
NeutralEvaxion's shares rose about 10% to $4.07 in Friday's pre-market session. The report gives no company update, so the move alone does not change Evaxion's business outlook.
12 health care stocks are changing a lot before the market opens on Friday.
NeutralEvaxion shares rose 15.35% in Friday's pre-market session. The article gives no company news, so this does not change its business outlook.
12 health care companies are changing prices before the market opens on Monday.
NeutralEvaxion shares rose about 11% before Monday's open, but the article gives no business reason, so its outlook is unchanged.
Complete transcript of Evaxion Biotech's earnings call for Q2 2026.
NeutralEvaxion Biotech's Q2 2026 earnings call highlighted a strong financial position with a net loss of $3.7 million and a cash runway extending into 2027. The company is making significant strides in its R&D pipeline, particularly with its cancer vaccines, and is positioned for future growth through strategic partnerships and recognition in the field.